Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DP007
- Development stage
- Preclinical
- Lead developer
- Bespak
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
DP007 is a climate-friendly, pressurized metered-dose inhaler (pMDI) formulation of albuterol, developed by DevPro Biopharma in collaboration with Bespak. Designed as a Ventolin-equivalent rescue inhaler, DP007 utilizes Honeywell's Solstice Air (HFO-1234ze(E) cGMP), a hydrofluoroolefin (HFO) propellant with near-zero global warming potential (GWP) that reduces greenhouse gas emissions by 99.9% compared to traditional hydrofluoroalkane (HFA) propellants. Albuterol acts as a selective beta-2 adrenergic receptor agonist, inducing bronchodilation to relieve bronchospasm. DP007 is currently in preclinical and IND-enabling development for the treatment of asthma and bronchospasm, with early feasibility studies completed.
- Other names
- albuterol pMDIalbuterol pressurized metered dose inhaler
02
Targets
ADRB2 (β2)
Beyond the preview
Go deeper on DP007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DP007.